16 November 2018 EMA/795349/2018 Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics EMA has reviewed serious, disabling and potentially permanent side effects with quinolone and fluoroquinolone antibiotics…
FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq) Safety Announcement [05-18-2018] The U.S. Food and Drug Administration (FDA) is alerting the public that serious cases of…
Kenya has been awarded as the 98th membership to the WHO Programme for International Drug Monitoring. Through a letter dated 4th May 2010, signed by Dr. Lembit Rägo, Coordinator, Quality Assurance and Safety: Medicines, Essential…
November 19, 2010 — The US Food and Drug Administration (FDA) has asked that propoxyphene, sold under the brand names Darvon and Darvocet by Xanodyne Pharmaceuticals, be removed from the US market. The decision will…

Introduction

The  Hospital Pharmacists Association of Kenya (HOPAK) provides a dynamic platform for the exchange of knowledge among sector players to enhance their contributions to health. We provide timely scientific programs, ongoing education, opportunities for networking, and professional development.

Our website is a resource portal for all practicing hospital and institutional pharmacists in Kenya.

Contact us

Hospital Pharmacists Association of Kenya (HOPAK)
P. O. Box 19859 00202
Nairobi - Kenya
info@hopak.or.ke